MA Pavilion Events-- Wednesday
Wednesday, June 20 2012
10:00 am – 5:00 pm
Location: BIO Exhibit Hall, Booth #0137
Please join us for these special events taking place inside Lifecycle Massachusetts: The Massachusetts Pavilion at the 2012 BIO International Convention (Booth #0137).
10 a.m. to 5 p.m.
Exhibition & Booth Partnering Open
10 a.m.- 12 p.m.
Coffee Break. Join us from 10 a.m. to 12 p.m. each day and enjoy complimentary coffee while visiting the Massachusetts Pavilion. Sponsored by The Bostonian Group.
Special announcement from Governor Patrick. Join us to find out what it is—Wednesday at 10 a.m.
11 a.m.- 1 p.m.
Global Connect. A series of meetings with international companies targeted for their potential to build or grow a presence in Massachusetts. Representatives from international companies are matched with representatives from the Massachusetts Office of International Trade and Investment, the Massachusetts Life Sciences Center and MassBio. Governor Deval Patrick, Boston Mayor Thomas Menino and other Massachusetts elected leaders and economic development officials will also participate.
Leading the Way: BioPharma Manufacturing in Massachusetts
New England is a global leader in biomanufacturing. This panel will discuss Massachusetts’ biomanufacturing capacity today and why it is particularly well positioned to meet manufacturing requirements in years ahead.
- Bill Aitchison, Head of Industrial Affairs, Genzyme
- Mark Trusheim, University of Massachusetts
- Ralph Lambalot, DVP Biologics Development & Manufacturing Launch, Abbott Laboratories
- Pat Sacco, Head of Manufacturing, Shire
- Vincent Donovan, Head of European and North American Regional Sales for BioPharm Process Solutions, EMD Millipore
- Moderator: Elisabeth Beck Reynolds, MIT & Biomanufacturing Roundtable
A Collaborative Approach to Preventing a Pre-Antibiotic Future
While the 20th Century will be credited for eradication or management of many of the world’s most devastating transmissible diseases - like Measles, Polio, Ricketts, and AIDS - the 21st Century may well be known for its neglect for failing to control infectious disease. What’s next in the development of new antibiotics needed to treat new and emerging resistant bugs? Hear from:
- Manos Perros, Site Head, Boston R&D, AstraZeneca Pharmaceuticals
- Ronnie Farquar, SVP, Discovery & Pharmaceutical Sciences, Cubist Pharmaceuticals
- Stephen B. Calderwood, MD, Physician and Chief, Division of Infectious Disease; Vice-Chair, Department of Medicine, Massachusetts General Hospital
- Moderator: Susan Windham Bannister, PhD, President & CEO, Massachusetts Life Sciences Center